Advances in the treatment of Benign Prostatic Hyperplasia: An integrative review
DOI:
https://doi.org/10.33448/rsd-v13i6.45877Keywords:
Benign prostatic hyperplasia; Treatment; Therapeutics; Drug therapy.Abstract
The condition known as benign prostatic hyperplasia (BPH) is a common occurrence in older men, characterized by the benign enlargement of the prostate, which can lead to bothersome urinary symptoms and significantly affect quality of life. BPH is a significant health concern worldwide, affecting the majority of older men to varying degrees. Although not fatal in itself, it can cause serious complications if not properly treated. Treatment for benign prostatic hyperplasia aims to alleviate symptoms, improve urinary function, and reduce the risk of associated complications. There are various treatment options available, ranging from non-invasive interventions to more complex surgical procedures, depending on the severity of symptoms and patient preferences. To initiate the review process, a search was conducted in the PubMed electronic database with the aim of identifying studies published in the last 3 years (2021 to 2024) that addressed advances in BPH treatment. The specific MESH descriptors used were "Benign Prostatic Hyperplasia", "Treatment", "Therapeutics", "Drug therapy". These terms were selected to ensure the inclusion of studies addressing different aspects related to BPH treatment, from new therapies to management guidelines and future predictions. The results of this review highlight the effectiveness of non-invasive interventions, such as lifestyle modifications and medication therapies, in improving urinary symptoms and quality of life in patients with mild to moderate BPH.
References
Baboudjian, M., Cornu, J. N., Gondran-Tellier, B., Fourmarier, M., Robert, G., Peyronnet, B., Misrai, V., & Pradere, B. (2023) Pharmacologic and Surgical Retreatment After Office-based Treatments for Benign Prostatic Hyperplasia: A Systematic Review. Eur Urol Focus. 9(5),727-733. 10.1016/j.euf.2023.03.004.
Cao, T., Xie, F., Shi, Y., Xu, J., Liu, Y., Cui, D., Zhang, F., Lin, L., Li, W., Gao, Y., Ruan, Y., Wang, X., Zhu, Y., Han, B., Xia, S., Guo, W., Li, B., & Jing Y. (2023) Rapamycin and Low-dose IL-2 Mediate an Immunosuppressive Microenvironment to Inhibit Benign Prostatic Hyperplasia. Int J Biol Sci. 19(11),3441-3455. 10.7150/ijbs.85089.
Crossetti, M. G. O. (2012). Revisión integrativa de la investigación en enfermería, el rigor científico que se le exige. Revista Gaúcha de Enfermagem, 33, 10- 11
Educação, Grupo Anima. (2014). Manual Revisão Bibliográfica Sistemática Integrativa: a pesquisa baseada em evidências. Grupo Anima Educação.
Hata J, Harigane Y, Matsuoka K, Akaihata H, Yaginuma K, Meguro S, Hoshi S, Sato Y, Ogawa S, Uemura M, & Kojima Y. (2023) Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia. Int J Mol Sci. 24(14),11634. 10.3390/ijms241411634.
Ji X, Zhao Y, Zhang L, & Liu Y. (2022) Benign prostatic hyperplasia wound after surgical removal in subjects on anticoagulant or antiplatelet therapy: A meta-analysis. Int Wound J. 19(8),1990-1999. 10.1111/iwj.13799.
Jin B. R, Kim H. J, Na J. H, Lee W. K, & An H. J. (2024) Targeting benign prostate hyperplasia treatments: AR/TGF-β/NOX4 inhibition by apocynin suppresses inflammation and proliferation. J Adv Res. 57:135-147. 10.1016/j.jare.2023.04.006.
Jin B. R, Lim C. . Y, Kim HJ, Lee M, & An H. J. (2023) Antioxidant mitoquinone suppresses benign prostatic hyperplasia by regulating the AR-NLRP3 pathway. Redox Biol. 65:102816. 10.1016/j.redox.2023.102816.
Jin R, Forbes C. M, Miller NL, Lafin J, Strand D. W, Case T, Cates J. M, Liu Q, Ramirez-Solano M, Mohler J. L, & Matusik R. J. T(2024) ranscriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance. Prostate. 84(5),441-459. 10.1002/pros.24661.
Joseph D. B., Henry G. H., Malewska A, Reese J. C., Mauck R. J., Gahan J. C., Hutchinson R. C., Mohler J. L., Roehrborn C. G., & Strand D. W. (2022) 5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia. J Pathol. 256(4),427-441. 10.1002/path.5857.
Kim, H. J., Jin, B. R., & An, H. J. (2023) Hesperidin ameliorates benign prostatic hyperplasia by attenuating cell proliferation, inflammatory response, and epithelial-mesenchymal transition via the TGF-β1/Smad signaling pathway. Biomed Pharmacother. 160:114389. 10.1016/j.biopha.2023.114389.
Lihua J, Haodan K, & Yuan X. U. (2023) Efficacy of Buzhong Yiqi decoction on benign prostatic hyperplasia and its possible mechanism. J Tradit Chin Med. 43(3),533-541. 10.19852/j.cnki.jtcm.2023.03.003.
Nygård, L. H., Talala, K., Taari, K., Tammela, T. L. J., Auvinen A, & Murtola T. J. (2023) Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia. Prostate. 83(3),246-258. 10.1002/pros.24456.
Park, W. Y., Song, G., Park, J. Y., Ahn, K. S., Kwak, H. J., Park, J., Lee, J. H., & Um, J. Y. (2022) Ellagic acid improves benign prostate hyperplasia by regulating androgen signaling and STAT3. Cell Death Dis. 13(6),554. 10.1038/s41419-022-04995-3.
Plochocki A, & King B. (2022) Medical Treatment of Benign Prostatic Hyperplasia. Urol Clin North Am. 49(2),231-238. 10.1016/j.ucl.2021.12.003.
Pompeo, D. A., Rossi, L. A., & Galvão, C. M. (2009). Revisão integrativa: etapa inicial do processo de validação de diagnóstico de enfermagem. Acta paulista de enfermagem, 22, 434-438. https://doi.org/10.1590/S0103-21002009000400014
Soares, C. B. et al. (2014). Revisão integrativa: conceitos e métodos utilizados na enfermagem. Revista da Escola de Enfermagem da USP, 48, 335-345.
Souza, M. T. de, Silva, M. D. da, & Carvalho, R. de. (2010). Revisão integrativa: o que é e como fazer. Einstein, 8, 102-106.
Stewart, K. L, & Lephart, E. D. (2023) Overview of BPH: Symptom Relief with Dietary Polyphenols, Vitamins and Phytochemicals by Nutraceutical Supplements with Implications to the Prostate Microbiome. Int J Mol Sci. 24(6),5486. 10.3390/ijms24065486.
Tawfik A, Abo-Elenen M, Gaber M, El-Abd A, Zoeir A, Saad S, Sultan I, & Ghoneim A. (2024) Tadalafil versus tamsulosin as combination therapy with 5-alpha reductase inhibitors in benign prostatic hyperplasia, urinary and sexual outcomes. World J Urol. 42(1),70. 10.1007/s00345-023-04735-y.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Fernanda Marinho de Souza; Paula Souza Sampaio; Miguel Fontana Pereira; Caio Márcio Coelho Alves
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
